FDA Grants Fast Track Designation to Debiopharm Group's Antibiotic Debio 1450
Lausanne, Switzerland (ots/PRNewswire) - - Debio 1450, oral/IV FabI inhibitor active against all Staphylococcus species has received Fast Track designation for ABSSSI (acute bacterial skin and skin structure infections) - Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) ...